Landherr László, Nagykálnai Tamás
Fôvárosi Onkormányzat Uzsoki utcai Kórháza Onkoradiológiai Központ, Budapest, Uzsoki.
Magy Onkol. 2009 Sep;53(3):237-46. doi: 10.1556/MOnkol.53.2009.3.1.
Chemotherapy options of metastatic colorectal cancer (mCRC) have been progressed rapidly in the last years. Besides of the standard fluorouracil/folinic acid treatment some new active agents (oxaliplatin and irinotecan) have been introduced, and more recently the "targeted" biologicals (bevacizumab, cetuximab, panitumumab) have demonstrated their high effectiveness. This review summarizes the development of the first line treatment of mCRC.
近年来，转移性结直肠癌（mCRC）的化疗方案进展迅速。除了标准的氟尿嘧啶/亚叶酸治疗外，一些新的活性药物（奥沙利铂和伊立替康）已被引入，最近，“靶向”生物制剂（贝伐单抗、西妥昔单抗、帕尼单抗）已证明其高效性。本综述总结了mCRC一线治疗的发展情况。
